Skip to main content
. 2021 Sep 2;24(4):552–564. doi: 10.1093/europace/euab200

Figure 3.

Figure 3

Use of any rate controlling therapies in patients randomized to early rhythm control (left panel) and usual care (right panel) in the EAST-AFNET 4 population. This display includes antiarrhythmic drugs with rate controlling properties, namely amiodarone, dronedarone, propafenone, and sotalol. The use of these medications often obviates the need for additional rate-controlling medication, explaining the lower use of beta blockers, calcium channel antagonists, or digoxin shown in A.